Labiotech.eu

News and Trends 6 Jan 2015

The largest VC investment in a single Biotech company has just been made

Wow, 2015 starts in a rush for the biotech industry. Moderna Therapeutics, Boston-based company led by French co-founding CEO Stephan Bancel just raised $450M (€380M) in VC investment. According to The Wall Street Journal, it is the largest VC-Investment ever made in a Biotech company. Moderna was founded only in 2011 and is an awesome company […]

January 6, 2015 - 1 minutemin - By Philip Hemme

News and Trends 22 Dec 2014

Biotech’s crowdfunding: is France top of the class?

No need to present the crowdfunding again! We hear about it every day through Kickstarter’s projects or other platforms that abound on the web. But what about biotech’s crowdfunding? Through many French entrepreneur’s interviews who are engaged in crowdfunding’s campaigns, I tried to make my own idea about this new financing tool. And one thing […]

December 22, 2014 - 5 minutesmins - By Joachim Eeckhout

News and Trends 20 Dec 2014

French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly

The French biotechnology company Adocia entered into an alliance with the US Eli Lilly on the co-development of an ultra-fast insulin to treat type 1 and type 2 diabetes. This insuline, called BioChaperone Lispro, has been developed through Adocia’s technology BioChaperone, is currently in Phase Ib clinical study. Under this global license agreement with Adocia, Eli Lilly […]

December 20, 2014 - 2 minutesmins - By Philip Hemme

News and Trends 19 Dec 2014

The French Leader in Insect Transformation Raised 5,5 Million Euros

Nine months after its first 1.8 million euros funding campaign, YNSECT, “The Insect Company”, a company specialized in insect biotechnology, has raised another 5.5 million euros. YNSECT is on its way to become a European and World leader in the insect field. The world is facing a major challenge: the food demand is expected to double by […]

December 19, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Dec 2014

An Effective Renewed Partnership for Treatment of Gynecological Cancers

Curie-Cancer, the part responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, extended their partnership to develop the 3C23K antibody for the treatment of gynecological cancers. An initial partnership agreement was concluded in 2013 and the results of work on the 3C23K antibody were presented to the Ovarian […]

December 16, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for a treatment against multiple sclerosis. Could GeNeuro become the next Merck-Serono? This amount will allow the Swiss company to continue the clinical development of this molecule. […]

December 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 11 Dec 2014

After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments

iTeos Therapeutics SA enters in a strategic collaboration with Pfizer Inc where iTeos will license to Pfizer rights to iTeos’ pre-clinical compounds targeting the enzymes expressed in many cancers. Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. It completes a previous deal with Merck a few weeks ago. Additionally, […]

December 11, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 10 Dec 2014

Promising Agreement Signed for Regenerative Medicine

Heraeus Medical signed an agreement with Locate Therapeutics to license the intellectual property surrounding the use of TAOS in orthopaedic applications and the inception of the first development program in this field. The agreement gives Heraeus Medical GmbH the rights to the future co-developed orthopaedic products as well as the processes involved in manufacturing the final product. […]

December 10, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 8 Dec 2014

An Orphan Drug Status Granted for the Leading Telormedix’s Cancer Treatment

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and infectious diseases, has obtained the orphan drug designation to Vesimune for the treatment of carcinoma in situ (CIS) in the bladder, by the U.S. Food and Drug Administration (FDA). Vesimune (TMX-101), is a proprietary targeted small molecule for the treatment of […]

December 8, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 7 Dec 2014

Ebola, the fever falls

This article provides an update of the 2014 Ebola outbreak relating to other past outbreaks of this disease. It provides demographic and economic insights into both the disease and the regions affected. It highlights lessons learnt and those that need to be learned. Which sectors are most impacted by this outbreak, and what is the […]

December 7, 2014 - 15 minutesmins - By Cédric Brock

News and Trends 6 Dec 2014

Alizé Pharma Acquires Exclusive Worldwide Rights on a New Peptide to Tackle Bone Diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties. The peptides are derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro […]

December 6, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 5 Dec 2014

Forbion Capital Partners: a Leading European Biotech VC is rising!

Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare technologies, sold PneumRx of its portfolio, to BTG plc, the UK-based specialist healthcare company for an initial cash consideration of €186M and up to €199M in performance-related future milestone payments. PneumRx is a growing interventional pulmonology business which owns, manufactures and distributes the RePneu Coil […]

December 5, 2014 - 3 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The largest VC investment in a single Biotech company has just been made

Biotech’s crowdfunding: is France top of the class?

French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly

The French Leader in Insect Transformation Raised 5,5 Million Euros

An Effective Renewed Partnership for Treatment of Gynecological Cancers

Will there be a New Merck-Serono?

After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments

Promising Agreement Signed for Regenerative Medicine

An Orphan Drug Status Granted for the Leading Telormedix’s Cancer Treatment

Ebola, the fever falls

Alizé Pharma Acquires Exclusive Worldwide Rights on a New Peptide to Tackle Bone Diseases

Forbion Capital Partners: a Leading European Biotech VC is rising!

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!